Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue SUPPL. 1, 2001, Pages

  Demeter, L ^a   Haubrich, R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

DNA amplification; Genotypic assays; IC50; Phenotypic assays; Sequencing

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ASSAY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT PLANNING; VIRUS INFECTION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MUTATION; REPRODUCIBILITY; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

EID: 0035280647     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103011-00002     Document Type: Review

References (31)

1. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
2. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
3. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
4. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
5. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1
6. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
7. The accuracy and reproducibility of high throughput genotypic and phenotypic HIV-1 resistance testing under EN45001 and CLIA accreditation labels
8. Reproducibility of an HIV phenotype resistance assay in clinical practice
9. A comparative analysis of Virco Antivirogram and Virologic PhenoSense phenotypic assays for drug susceptibility of HIV-1
10. Patents failing on stavudine-based therapies that have developed thymidine analogue mutations; multidrug resistance or V75T mutations have reduced phenotypic susceptibility to stavudine
11. Selection of zidovudine resistance mutations conferring low-level resistance to stavudine occurs at low frequency in stavudine-treated patients and in vitro during prolonged selection experiments
12. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
13. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006)
14. Baseline genotype and phenotype do not predict response to ABT-378/ritonavir in PI-experienced patients at 24 and 48 weeks
15. Identification of clinically relevant phenotypic and genotypic break-points for ABT-378/r in multiple PI-experienced, NNRTI-naive patients
16. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
17. Maintaining the integrity of human immunodeficiency virus sequence databases
18. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
19. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA
20. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
21. Second worldwide evaluation of HIV-1 drug resistance genotyping quality, using the ENVA-2 panel
22. A blinded comparative analysis of two genotyping service laboratories: Full sequence analysis of HIV-1 protease and reverse transcriptase
23. Proficiency testing of sequence-based genotypic assays
24. Differences in protease and reverse transcriptase sequences between TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystems)
25. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
26. L-2′, 3′-dideoxy-3′-thiacytidine
27. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
28. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype (Virtual Phenotype)
29. The application of neural networks in predicting phenotyic resistance from genotypes for HIV-1 protease inhibitors
30. HIV-1 reverse transcriptase and protease mutation Search Engine for Queries (HIV.SEQ)